Vivanza Biosci.

{
  "main_header": {
    "sid": 515837,
    "name": "Vivanza Biosci.",
    "stock_name": "Vivanza Biosci.",
    "full_name": "Vivanza Biosciences Ltd",
    "name_url": "stocks-analysis/vivanza-biosci",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1.85",
    "chg": 0.03,
    "chgp": "1.65%",
    "dir": 1,
    "prev_price": "1.82",
    "mcapval": "7.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530057,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 67,
    "indexname": "India SENSEX",
    "isin": "INE984E01035",
    "curr_date": "Mar 25",
    "curr_time": "",
    "bse_nse_vol": "29.91 k",
    "exc_status": "Active",
    "traded_date": "Mar 25, 2026",
    "traded_date_str": "2026 03 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vivanza Biosciences Ltd Valuation Shifts Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-amid-market-challenges-3909012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_valuationdot_3909012.png",
        "date": "2026-03-24 08:01:00",
        "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid persistent financial challenges and a deteriorating performance relative to peers and benchmarks."
      },
      {
        "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.82 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-stock-hits-52-week-low-amid-market-downturn-3907973",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_priceRelatedfactors_3907973.png",
        "date": "2026-03-23 13:08:27",
        "description": "For the fifth consecutive session, Vivanza Biosciences Ltd closed lower, slipping to a fresh 52-week low of Rs 1.82 on 23 Mar 2026 amid persistent selling pressure that outpaced its sector and the broader market."
      },
      {
        "title": "Vivanza Biosciences Ltd Valuation Shifts Signal Attractive Entry Amid Prolonged Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-attractive-entry-amid-prolonged-underperformance-3897896",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_valuationdot_3897896.png",
        "date": "2026-03-18 08:00:30",
        "description": "Vivanza Biosciences Ltd has witnessed a notable change in its valuation parameters, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios shifting towards a more attractive zone despite ongoing operational and financial headwinds. This development invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Vivanza Biosciences Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vivanza-biosciences-ltd-fallingrising-3895441",
        "imagepath": "",
        "date": "2026-03-17 01:16:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Persistent Downward Momentum</strong></p>\n<p>Vivanza Biosciences has been on a challenging trajectory over recent periods. The stock has declined by 1.55% over the past week, slightly outperforming the Sensex’s 2.66% fall during the same timeframe. However, over the last month, the stock’s losses have deepened to 9.52%, marginally worse than the Sensex’s 9.34% decline. Year-to-date, the stock has fallen 13.64%, underperforming the broader market index which has dropped 11.40%. This trend extends further back, with the stock down 11.63% over the last year, contrasting with the Sensex’s positive 2.27% gain. The longer-term picture is even more stark, as Vivanza Biosciences has lost over 85% of its value in the past five years, while the Sensex has nearly doubled in that period.</p>\n<p><strong>..."
      },
      {
        "title": "Vivanza Biosciences Falls 3.43%: Downgrade and Valuation Shift Mark a Challenging Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-343-downgrade-and-valuation-shift-mark-a-challenging-week-3891829",
        "imagepath": "",
        "date": "2026-03-14 17:21:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Mar:</strong> Downgrade to Strong Sell rating announced</p>\n                    <p><strong>4 Mar:</strong> Stock price rises modestly to Rs.1.98 (+1.02%)</p>\n                    <p><strong>5 Mar:</strong> Valuation grade shifts from attractive to fair</p>\n                    <p><strong>6 Mar:</strong> Week closes at Rs.1.97 (-1.50%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.04</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.97</div><div class=\"stat-change negative\">-3.4..."
      },
      {
        "title": "Vivanza Biosciences Ltd: Valuation Shift Signals Caution Amidst Weak Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shift-signals-caution-amidst-weak-returns-3872480",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_valuationdot_3872480.png",
        "date": "2026-03-05 08:00:46",
        "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 1.02% to close at ₹1.98, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture that investors must carefully analyse in the context of sector peers and historical performance."
      },
      {
        "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3865938",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VivanzaBioscien_mojoScore_3865938.png",
        "date": "2026-03-03 08:28:25",
        "description": "Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term performance, valuation metrics, and technical trends have prompted a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Vivanza Biosciences Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-a-detailed-analysis-of-the-rating-change-3857418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VivanzaBioscien_mojoScore_3857418.png",
        "date": "2026-02-26 08:10:11",
        "description": "Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a modest improvement in technical indicators amid persistent fundamental challenges. The pharmaceutical and biotechnology company’s overall Mojo Score rose to 34.0, signalling a cautious shift in market sentiment as technical trends show signs of stabilisation despite ongoing financial headwinds."
      },
      {
        "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3851068",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VivanzaBioscien_mojoScore_3851068.png",
        "date": "2026-02-23 08:08:24",
        "description": "Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Feb 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company continues to underperform its benchmark indices and peers, prompting a reassessment of its investment appeal."
      }
    ],
    "total": 176,
    "sid": "515837",
    "stock_news_url": "https://www.marketsmojo.com/news/vivanza-biosciences-515837"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Mar-2026",
      "details": "This is to Inform that pursuant to SEBI (PIT) Regulations 2015 read with the relevant Circulars issued by BSE Limited and Companies Code of Conduct for prevention of Insider Trading of the Company the Trading window for dealing in shares of the Company for all designated persons and their Immediate Relatives shall remain Closed from 1st April 2026 till 48 Hours after the Decleration of financial results for the Quarter and Year ended 31st March 2026. The date of the Board meeting for the consideration of the Financial Results of the Company for the Quarter ended 31st March 2026 will be intimated in due course.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
      "datetime": "17-Mar-2026",
      "details": "Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 We wish to inform you that Mr. Hemant Amrish Parikh (DIN: 00027820) has tendered his resignation as Non-Executive Director of the Company vide letter dated March 17th 2026 effective from the close of business hours on the same date citing personal reasons. The details required under Regulation 30 read with SEBI Circular are provided in Annexure-A. Further the Company has received confirmation from Mr. H.A. Parikh that there are no material reasons for his resignation other than those stated in his resignation letter dated March 17 2026 which is enclosed as Annexure-B",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
      "datetime": "17-Mar-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding intimation of Resignation of Mr. Hemant Amrish Parikh as Non-Executive Director with Effect from 17/03/2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23",
          "dt": "2023-03-24",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vivanza Biosciences Ltd Valuation Shifts Amid Market Challenges

2026-03-24 08:01:00

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid persistent financial challenges and a deteriorating performance relative to peers and benchmarks.

Read full news article

Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.82 as Sell-Off Deepens

2026-03-23 13:08:27

For the fifth consecutive session, Vivanza Biosciences Ltd closed lower, slipping to a fresh 52-week low of Rs 1.82 on 23 Mar 2026 amid persistent selling pressure that outpaced its sector and the broader market.

Read full news article

Vivanza Biosciences Ltd Valuation Shifts Signal Attractive Entry Amid Prolonged Underperformance

2026-03-18 08:00:30

Vivanza Biosciences Ltd has witnessed a notable change in its valuation parameters, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios shifting towards a more attractive zone despite ongoing operational and financial headwinds. This development invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

Why is Vivanza Biosciences Ltd falling/rising?

2026-03-17 01:16:06

Persistent Downward Momentum

Vivanza Biosciences has been on a challenging trajectory over recent periods. The stock has declined by 1.55% over the past week, slightly outperforming the Sensex’s 2.66% fall during the same timeframe. However, over the last month, the stock’s losses have deepened to 9.52%, marginally worse than the Sensex’s 9.34% decline. Year-to-date, the stock has fallen 13.64%, underperforming the broader market index which has dropped 11.40%. This trend extends further back, with the stock down 11.63% over the last year, contrasting with the Sensex’s positive 2.27% gain. The longer-term picture is even more stark, as Vivanza Biosciences has lost over 85% of its value in the past five years, while the Sensex has nearly doubled in that period.

...

Read full news article

Vivanza Biosciences Falls 3.43%: Downgrade and Valuation Shift Mark a Challenging Week

2026-03-14 17:21:51

Key Events This Week

2 Mar: Downgrade to Strong Sell rating announced

4 Mar: Stock price rises modestly to Rs.1.98 (+1.02%)

5 Mar: Valuation grade shifts from attractive to fair

6 Mar: Week closes at Rs.1.97 (-1.50%)

Week Open

Rs.2.04

Week Close

Rs.1.97

-3.4...

Read full news article

Vivanza Biosciences Ltd: Valuation Shift Signals Caution Amidst Weak Returns

2026-03-05 08:00:46

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a modest day gain of 1.02% to close at ₹1.98, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture that investors must carefully analyse in the context of sector peers and historical performance.

Read full news article

Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-03-03 08:28:25

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 2 March 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s long-term performance, valuation metrics, and technical trends have prompted a reassessment of its investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

Vivanza Biosciences Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change

2026-02-26 08:10:11

Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a modest improvement in technical indicators amid persistent fundamental challenges. The pharmaceutical and biotechnology company’s overall Mojo Score rose to 34.0, signalling a cautious shift in market sentiment as technical trends show signs of stabilisation despite ongoing financial headwinds.

Read full news article

Vivanza Biosciences Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-02-23 08:08:24

Vivanza Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Feb 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company continues to underperform its benchmark indices and peers, prompting a reassessment of its investment appeal.

Read full news article

View All News